Treatment of refractory juvenile dermatomyositis with tacrolimus

Jafari, Hassan; Net, J van der; Royen-Kerkhof, A van

doi:10.1186/1546-0096-6-s1-p215

Cited by 12 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the usefulness of MMF has been reported by case series studies (evidence level V) . Other case reports have described the usefulness of CsA and Tac for the treatment of the skin lesions (evidence level V) . In use of these drugs, careful attention should be paid to possible adverse reactions.…”

Section: Methodsmentioning

confidence: 99%

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Kohsaka

Mimori

Kanda³

et al. 2018

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

Although rheumatologists, neurologists, and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of this study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor, and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology, and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations, and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time.

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Kohsaka

Mimori

Kanda³

et al. 2018

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

show abstract

“…70,195 Other case reports have described the usefulness of CsA and Tac for the treatment of the skin lesions (evidence level V). [196][197][198] In use of these drugs, careful attention should be paid to possible adverse reactions.…”

Section: Cq21 How Should Dm Patients Only Exhibiting Skin Manifestatmentioning

confidence: 99%

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Kohsaka

Mimori

Kanda

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time.

show abstract

“…A few case series have documented efficacy with this drug, particularly in cases of refractory muscle disease in JDM . In addition, a seemingly impressive resolution of skin lesions has been reported in several cases of JDM, including cutaneous calcinosis and vasculitis . In adults, tacrolimus has also been reported to be effective in ILD and myositis associated with the inflammatory myopathies .…”

Section: Calcineurin Inhibitorsmentioning

confidence: 99%

Management of cutaneous dermatomyositis

Lam

Vleugels

2012

Dermatol Ther

View full text Add to dashboard Cite

Dermatomyositis (DM) is traditionally classified as an idiopathic inflammatory myopathy distinguished by muscle weakness and characteristic cutaneous findings. Patients presenting with the skin manifestations in the absence of clinical evidence of muscle weakness are categorized as clinically amyopathic DM. The symptoms associated with the cutaneous findings can be particularly debilitating, and a discordant response to therapy exists between muscle and skin disease. Various therapeutic agents and treatment approaches have been described, both for the cutaneous and extracutaneous manifestations; however, a paucity of controlled studies in this disease leads to limitations in interpreting the available data. In this review, emphasis is placed specifically on summarizing the current literature regarding management of cutaneous DM. In addition, an algorithmic approach to treatment of skin disease is presented.

show abstract

Treatment of refractory juvenile dermatomyositis with tacrolimus

Cited by 12 publications

References 0 publications

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

Management of cutaneous dermatomyositis

Contact Info

Product

Resources

About